The content on this site is intended for healthcare professionals only
This interesting presentation addresses the important question of whether health care systems can afford the new treatments emerging in CLL. What is clearly good for patient care provides a challenge for the health economy.
Dr Follows explains how cost-effectiveness is calculated, eg, according to Quality Adjusted Life Years – QALY, and Incremental Cost-Effectiveness Ratio - ICER.
He outlines the challenges of calculating cost-effectiveness for CLL drug regimens, including how similar patients in clinic are from the clinical trial study population.
He also addresses the balance needed in health economics in CLL between life expectancy, age and co-morbidities.
Content taken from a Mundipharma sponsored satellite symposium at iwCLL 2013 as part of the official programme.
Boosting HPV vaccination in India: A call to action
Legislation – a powerful tool for promoting massive changes
Gaza's cancer patients: Navigating the dual struggle of illness and war
Tackling breast cancer screening in conservative communities
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India
Cancer in emergencies: What can we do better to protect the most vulnerable?
Tele-mentoring: Impact of project ECHO
Empowering cancer survivorship: collaboration and care
Haemopathy burden in the National Cancer Center of Cambodia
